The Federal Court issued two Practice Notices today:
Bill C-11, the Digital Charter Implementation Act, was introduced today directed to a new privacy regime, including the Consumer Privacy Protection Act, the Personal Information and Data Protection Tribunal Act, and replacing parts of PIPEDA. Key features include a tribunal that can impose significant fines, order-making power by the Privacy Commissioner, disclosure of “automated decision systems”, data mobility and de-identification uses.
Bill C-4 was introduced today to implement the Canada-US-Mexico trade agreement. The IP related changes are substantially the same as those included in Bill C-100 introduced last May. Bill C-4 include a new criminal provisions on trade secrets, trademark changes on importation and in-transit goods, and some changes on copyright term (although not a general extension to life+70).
CIPO posted new and amended practice notices for several aspects of trademark procedures:
- extensions of time in examination – the office will no longer grant extensions of time unless exceptional circumstances are shown;
- filing of divisional applications without a specific e-service;
- transitional provisions for Nice classifications;
- renewal of applications that do not have Nice classifications; and
- temporarily appointing a trademark agent for dealing with Nice classifications.
The long awaited amendments to the Patent Act and Rules came into force today. Hopefully by now, none of my subscribers need a summary of the changes.
As published in the Canada Gazette last week, amendments to the Bankruptcy and Insolvency Act (BIA) and Companies’ Creditors Arrangement Act (CCAA) relating to IP licenses when the IP licensor becomes insolvent, will come into force November 1, 2019. These amendments were included in Budget Implementation Act, 2018, No. 2 (Bill C-86). I discussed these amendments in my recent article for Slaw, Intellectual Property Licenses in Bankruptcy Scenarios.
The final amendments to the Patented Medicines Regulations have been published, coming into force July 1, 2020. The regulations relate to the factors and procedures to be considered by the Patented Medicines Prices Review Board. Continue reading Patented Medicines